Skip to main content Accessibility help
×
Home
  • Print publication year: 2011
  • Online publication date: December 2011

22 - Management of aneurysmal subarachnoid haemorrhage in the neurointensive care unit

from Section 4 - Neurointensive care

Related content

Powered by UNSILO

Further reading

Anon. (2000). Epidemiology of aneurysmal subarachnoid hemorrhage in Australia and New Zealand: incidence and case fatality from the Australasian Cooperative Research on Subarachnoid Hemorrhage Study (ACROSS). Stroke 31, 1843–50.
Baldwin, M. E., Macdonald, R. L. and Huo, D. (2004). Early vasospasm on admission angiography in patients with aneurysmal subarachnoid hemorrhage is a predictor for in-hospital complications and poor outcome. Stroke 35, 2506–11.
Barker, F. G. II and Ogilvy, C. S. (1996). Efficacy of prophylactic nimodipine for delayed ischemic deficit after subarachnoid hemorrhage: a metaanalysis. J Neurosurg 84, 405–14.
Charpentier, C., Audibert, G., Guillemin, F. et al. (1999). Multivariate analysis of predictors of cerebral vasospasm occurrence after aneurismal subarachnoid hemorrhage. Stroke 30, 1402–8.
Crompton, M. R. (1964). The pathogenisis of cerebral infarction following the rupture of cerebral aneurysms. Brain 87, 491–510.
Cross, D. T. III, Tirschwell, D. L., Clark, M. A. et al. (2003). Mortality rates after subarachnoid hemorrhage: variations according to hospital case volume in 18 states. J Neurosurg 99, 810–17.
Dennis, L. J., Claassen, J., Hirsch, L. J. et al. (2002). Nonconvulsive status epilepticus after subarachnoid hemorrhage. Neurosurgery 51, 1136–43.
Ghali, J. K., Koren, M. J., Taylor, J. R. et al. (2006). Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab 91, 2145–52.
Groden, C., Kremer, C., Regelsberger, J. et al. (2001). Comparison of operative and endovascular treatment of anterior circulation aneurysms in patients in poor grades. Neuroradiology 43, 778–83.
Gruber, A., Ungersbock, K., Reinprecht, A. et al. (1998). Evaluation of cerebral vasospasm after early surgical and endovascular treatment of ruptured intracranial aneurysms. Neurosurgery 42, 258–67.
Knuckey, N. W. and Stokes, B. A. (1982). Medical management of patients following a ruptured cerebral aneurysm, with epsilon-aminocaproic acid, kanamycin, and reserpine. Surg Neurol 17, 181–5.
Kostron, H., Twerdy, K. and Grunert, V. (1988). The calcium entry blocker nimodipine improves the quality of life of patients operated on for cerebral aneurysms. A 5-year follow-up analysis. Neurochirurgia 31, 150–3.
Kramer, A. H., Gurka, M. J., Nathan, B. et al. (2008). Complications associated with anemia and blood transfusion in patients with aneurysmal subarachnoid hemorrhage. Crit Care Med 36, 2070–5.
Lin, C. L., Shih, H. C., Lieu, A. S. et al. (2007). Attenuation of experimental subarachnoid hemorrhage-induced cerebral vasospasm by the adenosine A2A receptor agonist CGS 21680. J Neurosurg; 106, 436–41.
Lysakowski, C., Walder, B., Costanza, M. C. et al. (2001). Transcranial Doppler versus angiography in patients with vasospasm due to a ruptured cerebral aneurysm: a systematic review. Stroke 32, 2292–8.
Manno, E. M., Gress, D. R., Schwamm, L. H. et al. (1998). Effects of induced hypertension on transcranial Doppler ultrasound velocities in patients after subarachnoid hemorrhage. Stroke 29, 422–8.
McGirt, M. J., Pradilla, G., Legnani, F. G. et al. (2006). Systemic administration of simvastatin after the onset of experimental subarachnoid hemorrhage attenuates cerebral vasospasm. Neurosurgery 58, 945–95.
Molyneux, A., Kerr, R., Ly-Mee, Y. et al. (2005). International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomized comparison of effects on survival, dependency, seizures, rebleeding, subgroups, and aneurysm occlusion. Lancet 366, 809–17.
Naidech, A. M., Drescher, J., Tamul, P. et al. (2006). Acute physiological derangement is associated with early radiographic cerebral infarction after SAH. J Neurol Neurosurg Psychiatry; 77, 1340–4.
Oddo, M., Milby, A. and Chen, I. (2009). Hemoglobin concentration and cerebral metabolism in patients with aneurysmal subarachnoid hemorrhage Stroke. 40, 75–1281.
Philippon, J., Grob, R., Dagreou, F. et al. (1986). Prevention of vasospasm in subarachnoid haemorrhage. A controlled study with nimodipine. Acta Neurochir 82, 110–14.
Pickard, J. D., Murray, G. D., Illingworth, R. et al. (1989). Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. BMJ 298, 636–42.
Proust, F., Callonec, F., Clavier, E. et al. (1999). Usefulness of transcranial color-coded sonography in the diagnosis of cerebral vasospasm. Stroke 30, 1091–8.
Sarrafzadeh, A. S., Sakowitz, O. W., Kiening, K. L. et al. (2002). Bedside microdialysis: a tool to monitor cerebral metabolism in subarachnoid hemorrhage patients? Crit Care Med 30, 1062–70.
Siironen, J., Juvela, S., Varis, J. et al. (2003). No effect of enoxaparin on outcome of aneurismal subarachnoid hemorrhage: a randomized, double-blind, placebo-controlled clinical trial. J Neurosurg 99, 953–9.
Skjoth-Rasmussen, J., Schulz, M., Kristensen, S. R. et al. (2004). Delayed neurological deficits detected by an ischemic pattern in the extracellular cerebral metabolites in patients with aneurysmal subarachnoid hemorrhage. J Neurosurg 100, 8–15.
Springborg, J. B., Moller, C., Gideon, P. et al. (2007). Erythropoietin in patients with aneurysmal subarachnoid haemorrhage: a double blind randomised clinical trial. Acta Neurochir Wein 149, 1089–101.
Treggiari, M. M., Walder, B., Suter, P. M. et al. (2003). Systematic review of the prevention of delayed ischemic neurological deficits with hypertension, hypervolemia, and hemodilution therapy following subarachnoid hemorrhage. J Neurosurg 98, 978–84.
Tseng, M. Y., Al-Rawi, P. G., Pickard, J. D. et al. (2003). Effect of hypertonic saline on cerebral blood flow in poor-grade patients with subarachnoid hemorrhage. Stroke 34, 1389–96.
Tseng, M. Y., Czosnyka, M., Richards, H. et al. (2005). Effects of acute treatment with pravastatin on cerebral vasospasm, autoregulation, and delayed ischemic deficits after aneurysmal subarachnoid hemorrhage: a phase II randomized placebo-controlled trial. Stroke 36, 1627–32.
Vajkoczy, P., Horn, P. and Thome, C. (2003). Regional cerebral blood flow monitoring in the diagnosis of delayed ischemia following aneurysmal subarachnoid hemorrhage. J Neurosurg 98, 1227–34.
Vatter, H., Zimmermann, M., Tesanovic, V. et al. (2005). Cerebrovascular characterization of clazosentan, the first nonpeptide endothelin receptor antagonist shown to be clinically effective for the treatment of cerebral vasospasm. Part II: Effect on endothelin(B) receptor-mediated relaxation. J Neurosurg 102, 1108–14.
Wong, G. K., Chan, M. T., Poon, W. S. et al. (2006). Magnesium therapy within 48 hours of an aneurysmal subarachnoid hemorrhage: neuro-panacea. Neurol Res 28, 431–5.
Zhang, Y., Milatovic, D., Aschner, M. et al. (2007). Neuroprotection by tamoxifen in focal cerebral ischemia is not mediated by an agonist action at estrogen receptors but is associated with antioxidant activity. Exp Neurol 204, 819–27.